![Llinos Honeybun](https://profiles-cardiff.imgix.net/attachments/6654?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Llinos Honeybun
- Welsh speaking
Teams and roles for Llinos Honeybun
Research Associate
School of Biosciences
Overview
I'm a research associate at the Medicines Discovery Institute (MDI) working on lysosomal disorders.
My PhD project with Prof Emyr Lloyd-Evans investigated novel treatments for a rare childhood neurodegenerative disorder called CLN3 disease (also referred to as Batten disease). This disorder affects children from the age of 4+ and symptoms include loss of vision, seizures and later, motor and cognitive decline. I developed and undertook a high throughput drug screen to uncover compounds that could be repurposed for CLN3 disease.
Publication
2023
- Lloyd-Evans, E., Best, H. L., Alshehri, A. S., Honeybun, L. and Waller-Evans, H. 2023. Glycosphingolipid reduction with miglustat as a therapeutic strategy for CLN3 and other neuronal ceroid lipofuscinoses.. Presented at: 19th Annual WORLDSymposium™ 2023, Orlando, Florida, 21-26 February 2023, Vol. 138. Vol. 2. Elsevier pp. 84., (10.1016/j.ymgme.2022.107212)
- Waller-Evans, H., Zhu, J., Honeybun, L., Gardiner, S., Hanley, M., Best, H. and Lloyd-Evans, E. 2023. Measuring ion flux via lysosomal channels: Primary and secondary assays for drug discovery across the lysosomal disorders. Presented at: 19th Annual WORLDSymposium™ 2023, Orlando, Florida, 21-26 February 2023, Vol. 138. Vol. 2. Elsevier pp. 133-134., (10.1016/j.ymgme.2022.107353)
- Honeybun, L., Waller-Evans, H. and Lloyd-Evans, E. 2023. Unbiased phenotypic drug screen for CLN3 disease. Presented at: 19th Annual WORLDSymposium™ 2023, Orlando, Florida, 21-26 February 2023, Vol. 138. Vol. 2. Elsevier pp. 167-167., (10.1016/j.ymgme.2022.107150)
- Best, H., Honeybun, L., Waller-Evans, H. and Lloyd-Evans, E. 2023. The Batten disease associated protein CLN3 is required for the efflux of lysosomal K. Presented at: 19th Annual WORLDSymposium™ 2023, Orlando, Florida, 21-26 February 2023, Vol. 138. Vol. 2. Elsevier pp. 47-47., (10.1016/j.ymgme.2022.107030)
Conferences
- Lloyd-Evans, E., Best, H. L., Alshehri, A. S., Honeybun, L. and Waller-Evans, H. 2023. Glycosphingolipid reduction with miglustat as a therapeutic strategy for CLN3 and other neuronal ceroid lipofuscinoses.. Presented at: 19th Annual WORLDSymposium™ 2023, Orlando, Florida, 21-26 February 2023, Vol. 138. Vol. 2. Elsevier pp. 84., (10.1016/j.ymgme.2022.107212)
- Waller-Evans, H., Zhu, J., Honeybun, L., Gardiner, S., Hanley, M., Best, H. and Lloyd-Evans, E. 2023. Measuring ion flux via lysosomal channels: Primary and secondary assays for drug discovery across the lysosomal disorders. Presented at: 19th Annual WORLDSymposium™ 2023, Orlando, Florida, 21-26 February 2023, Vol. 138. Vol. 2. Elsevier pp. 133-134., (10.1016/j.ymgme.2022.107353)
- Honeybun, L., Waller-Evans, H. and Lloyd-Evans, E. 2023. Unbiased phenotypic drug screen for CLN3 disease. Presented at: 19th Annual WORLDSymposium™ 2023, Orlando, Florida, 21-26 February 2023, Vol. 138. Vol. 2. Elsevier pp. 167-167., (10.1016/j.ymgme.2022.107150)
- Best, H., Honeybun, L., Waller-Evans, H. and Lloyd-Evans, E. 2023. The Batten disease associated protein CLN3 is required for the efflux of lysosomal K. Presented at: 19th Annual WORLDSymposium™ 2023, Orlando, Florida, 21-26 February 2023, Vol. 138. Vol. 2. Elsevier pp. 47-47., (10.1016/j.ymgme.2022.107030)
Research
Biography
PhD Student (2021-2025). I characterised CLN3 disease cells phenotypically through microscopy and developed a drug-screening assay to identify compounds suitable for reppurposing. I completed the drug screening at a specialist high throughput drug screening facility in Vancouver, Canada.
Genetic Technologist at the All Wales Medial Genomics Service at NHS Wales (2019-2021). I was part of the clinical team analysing patient genetic data to provide targeted cancer treatment for patients with specific genetic mutations.
Development Scientist at BBI Solutions (2017-2019). Here I developed several lateral flow device technologies for many different markers from proof of concept to validation.
MSc Forensic Science at Strathclyde University (2017). My research project investigated post-mortem drug re-distribution through non-destructive X-Ray CT scanning.
BSc Pharmacology at Bath University (2016) with a placement year at Cardiff University investigating the role of endocytosis on Alzheimer's disease. My final year project looked at alternative therapies for epilepsy using electrophysiology techniques on brain slices.
Contact Details
Research themes
Specialisms
- Animal cell and molecular biology
- Fluorescence microscopy
- Translational Drug Discovery
- Drug Screening